Amedeo Smart

Free Medical Literature Service



Hepatitis C

  Free Subscription

Articles published in
PLoS One
    January 2021
  1. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    >> Share

  2. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    >> Share

  3. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    >> Share

  4. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    >> Share

  5. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    >> Share

  6. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    >> Share

  7. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    >> Share

  8. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    >> Share

  9. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    >> Share

  10. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.
    >> Share

  11. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    >> Share

  12. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    >> Share

  13. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    >> Share

  14. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    >> Share

  15. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    >> Share

  16. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    >> Share

  17. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    >> Share

  18. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    >> Share

  19. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    >> Share

  20. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    >> Share

  21. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    >> Share

  22. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    >> Share

  23. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    >> Share

  24. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    >> Share

  25. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    >> Share

  26. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    >> Share

  27. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    >> Share

  28. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    >> Share

  29. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    >> Share

  30. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    >> Share

  31. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    >> Share

  32. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    >> Share

  33. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    >> Share

  34. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    >> Share

  35. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    >> Share

  36. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    >> Share

  37. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    >> Share

  38. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    >> Share

  39. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    >> Share

  40. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    >> Share

  41. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    >> Share

  42. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    >> Share

  43. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    >> Share

  44. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    >> Share

  45. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    >> Share

  46. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    >> Share

  47. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    >> Share

  48. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    >> Share

  49. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    >> Share

  50. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    >> Share

    January 2020
  51. RIVERO-JUAREZ A, Guijo-Rubio D, Tellez F, Palacios R, et al
    Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals.
    PLoS One. 2020;15:e0227188.
    >> Share

  52. TSAI WL, Wang CF, Cheng JS, Chen WC, et al
    Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
    PLoS One. 2020;15:e0227424.
    >> Share

  53. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    >> Share

  54. GOOD SS, Moussa A, Zhou XJ, Pietropaolo K, et al
    Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    PLoS One. 2020;15:e0227104.
    >> Share

  55. NUTINI MFR, Hunter J, Giron L, Pires AFNPC, et al
    HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country.
    PLoS One. 2020;15:e0227082.
    >> Share

  56. LIU GY, Tang O, Brotman DJ, Miller ER 3rd, et al
    Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.
    PLoS One. 2020;15:e0224977.
    >> Share

  57. HUHN GD, Ramgopal M, Jain MK, Hinestrosa F, et al
    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PLoS One. 2020;15:e0224875.
    >> Share

  58. SAINE ME, Moore TM, Szymczak JE, Bamford LP, et al
    Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.
    PLoS One. 2020;15:e0228471.
    >> Share

  59. PATEL SV, Jayaweera DT, Althoff KN, Eron JJ, et al
    Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PLoS One. 2020;15:e0228847.
    >> Share

  60. LEE KS, Quintiliani L, Heinz A, Johnson NL, et al
    A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PLoS One. 2020;15:e0228767.
    >> Share

  61. CARVALHO-GOMES A, Cubells A, Pallares C, Hontangas V, et al
    A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
    PLoS One. 2020;15:e0228351.
    >> Share

  62. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    >> Share

  63. CASTRO R, Perazzo H, de Araujo LAMM, Gutierres IG, et al
    Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
    PLoS One. 2020;15:e0229143.
    >> Share

  64. LIN SF, Tung SY, Wei KL, Chen CH, et al
    Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    PLoS One. 2020;15:e0229994.
    >> Share

  65. SCHMIDBAUER C, Schubert R, Schutz A, Schwanke C, et al
    Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    PLoS One. 2020;15:e0229239.
    >> Share

  66. KHAN HU, Khan S, Shah MA, Attaullah S, et al
    Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients.
    PLoS One. 2020;15:e0231480.
    >> Share

  67. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    >> Share

  68. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    >> Share

  69. WILLIAMS SH, Levy A, Yates RA, Somaweera N, et al
    Discovery of Jogalong virus, a novel hepacivirus identified in a Culex annulirostris (Skuse) mosquito from the Kimberley region of Western Australia.
    PLoS One. 2020;15:e0227114.
    >> Share

  70. PRINSENBERG T, Rebers S, Boyd A, Zuure F, et al
    Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection.
    PLoS One. 2020;15:e0231385.
    >> Share

  71. CHIU SM, Tsai MC, Lin CY, Chen CH, et al
    Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.
    PLoS One. 2020;15:e0231102.
    >> Share

  72. KRACHT PAM, Arends JE, Hoepelman AIM, Vervoort SCJM, et al
    The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.
    PLoS One. 2020;15:e0230756.
    >> Share

  73. WEITZEL T, Rodriguez F, Noriega LM, Marcotti A, et al
    Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey.
    PLoS One. 2020;15:e0227776.
    >> Share

  74. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    >> Share

  75. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    >> Share

  76. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Treatment and re-treatment results of HCV patients in the DAA era.
    PLoS One. 2020;15:e0232773.
    >> Share

  77. AKHTAR S, Nasir JA, Usman M, Sarwar A, et al
    The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0232931.
    >> Share

  78. NGUYEN DT, Tran TTT, Nghiem NM, Le PT, et al
    Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PLoS One. 2020;15:e0233446.
    >> Share

  79. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    >> Share

  80. LIN WC, Lin YS, Chang CW, Chang CW, et al
    Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0233212.
    >> Share

  81. MORISHITA N, Sakamori R, Yamada T, Kai Y, et al
    Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    PLoS One. 2020;15:e0234811.
    >> Share

  82. STEFFEN G, Sperle I, Leendertz SA, Sarma N, et al
    The epidemiology of Hepatitis B, C and D in Germany: A scoping review.
    PLoS One. 2020;15:e0229166.
    >> Share

  83. DURACINSKY M, Thonon F, Bun S, Ben Nasr I, et al
    Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study.
    PLoS One. 2020;15:e0235260.
    >> Share

  84. Retraction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2020;15:e0235375.
    >> Share

  85. BRAIN D, Mitchell J, O'Beirne J
    Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.
    PLoS One. 2020;15:e0234577.
    >> Share

  86. LEE MH, Lee GA, Lee SH, Park YH, et al
    A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: Back to basics of infection control.
    PLoS One. 2020;15:e0229911.
    >> Share

  87. TRAEGER MW, Pedrana AE, van Santen DK, Doyle JS, et al
    The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    PLoS One. 2020;15:e0235445.
    >> Share

  88. ZHANG Y, Gao Z, Wang S, Liu J, et al
    Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion.
    PLoS One. 2020;15:e0235612.
    >> Share

  89. COPPOCK D, Chou E, Gracely E, Gross R, et al
    Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.
    PLoS One. 2020;15:e0235778.
    >> Share

  90. TRONINA O, Gotlib J, Malkowski P, Jaworski M, et al
    Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.
    PLoS One. 2020;15:e0235764.
    >> Share

  91. LI H, Marks KM, Talal AH, van Seggelen WO, et al
    Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing.
    PLoS One. 2020;15:e0235237.
    >> Share

  92. TRAN HTL, Morikawa K, Anggakusuma, Zibi R, et al
    OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    PLoS One. 2020;15:e0236447.
    >> Share

  93. PEREIRA FM, Almeida MDCC, Santos FLN, Carreiro RP, et al
    Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.
    PLoS One. 2020;15:e0223087.
    >> Share

  94. SHAWON MA, Yousuf MAK, Raheem E, Ahmed S, et al
    Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.
    PLoS One. 2020;15:e0232121.
    >> Share

  95. SAITO K, Fukasawa M, Shirasago Y, Suzuki R, et al
    Comparative characterization of flavivirus production in two cell lines: Human hepatoma-derived Huh7.5.1-8 and African green monkey kidney-derived Vero.
    PLoS One. 2020;15:e0232274.
    >> Share

  96. PALAYEW A, Stumo SR, Cooke GS, Hutchinson SJ, et al
    The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    PLoS One. 2020;15:e0235715.
    >> Share

  97. NGWAGA T, Kong L, Lin D, Schoborg C, et al
    Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PLoS One. 2020;15:e0237162.
    >> Share

  98. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    >> Share

  99. YEN HH, Su PY, Zeng YH, Liu IL, et al
    Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
    PLoS One. 2020;15:e0237582.
    >> Share

  100. BOBARDT M, Hansson MJ, Mayo P, Ure D, et al
    Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
    PLoS One. 2020;15:e0237236.
    >> Share

  101. JEPKEMEI KB, Ochwoto M, Swidinsky K, Day J, et al
    Characterization of occult hepatitis B in high-risk populations in Kenya.
    PLoS One. 2020;15:e0233727.
    >> Share

  102. RUIZ-EXTREMERA A, Diaz-Alcazar MDM, Munoz-Gamez JA, Cabrera-Lafuente M, et al
    Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.
    PLoS One. 2020;15:e0233528.
    >> Share

  103. FAGUNDES RN, Ferreira LEVVC, Pace FHL
    Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PLoS One. 2020;15:e0237005.
    >> Share

  104. ASHHAB AA, Rodin H, Campos M, Abu-Sulb A, et al
    Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
    PLoS One. 2020;15:e0237398.
    >> Share

  105. DUCHESNE L, Hejblum G, Njouom R, Toure Kane C, et al
    Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    PLoS One. 2020;15:e0238035.
    >> Share

  106. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    >> Share

  107. CABEZAS C, Trujillo O, Gonzales-Vivanco A, Benites Villafane CM, et al
    Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2020;15:e0234273.
    >> Share

  108. ANDERSON ES, Russell C, Basham K, Montgomery M, et al
    High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department.
    PLoS One. 2020;15:e0233927.
    >> Share

  109. NIELSEN S, Hansen JF, Hay G, Cowan S, et al
    Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
    PLoS One. 2020;15:e0238203.
    >> Share

  110. READY E, Habecker P, Abadie R, Khan B, et al
    Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs.
    PLoS One. 2020;15:e0235124.
    >> Share

    Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia.
    PLoS One. 2020;15:e0234822.
    >> Share

  112. LI J, Abosmaha E, Coffin CS, Labonte P, et al
    Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes.
    PLoS One. 2020;15:e0239153.
    >> Share

  113. JARGALSAIKHAN G, Eichner M, Boldbaatar D, Bat-Ulzii P, et al
    Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.
    PLoS One. 2020;15:e0235036.
    >> Share

    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    >> Share

  115. OYAMA M, Ohnuki Y, Inoue M, Uruha A, et al
    HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis.
    PLoS One. 2020;15:e0237890.
    >> Share

  116. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    >> Share

  117. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    >> Share

  118. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    >> Share

  119. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    >> Share

  120. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    >> Share

  121. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    >> Share

  122. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    >> Share

  123. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    >> Share

  124. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    >> Share

  125. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    >> Share

  126. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    >> Share

  127. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    >> Share

  128. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    >> Share

  129. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    >> Share

  130. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    >> Share

  131. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    >> Share

  132. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    >> Share

  133. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    >> Share

  134. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    >> Share

  135. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    >> Share

  136. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    >> Share

    January 2019
  137. FOSTER GR, Asselah T, Kopecky-Bromberg S, Lei Y, et al
    Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    PLoS One. 2019;14:e0208506.
    >> Share

  138. POPPING S, Hullegie SJ, Boerekamps A, Rijnders BJA, et al
    Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
    PLoS One. 2019;14:e0210179.
    >> Share

  139. YEN YH, Kee KM, Chen CH, Hu TH, et al
    Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PLoS One. 2019;14:e0208858.
    >> Share

  140. KONERMAN MA, Beste LA, Van T, Liu B, et al
    Machine learning models to predict disease progression among veterans with hepatitis C virus.
    PLoS One. 2019;14:e0208141.
    >> Share

  141. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0210173.
    >> Share

  142. MANE A, Sacks J, Sharma S, Singh H, et al
    Evaluation of five rapid diagnostic tests for detection of antibodies to hepatitis C virus (HCV): A step towards scale-up of HCV screening efforts in India.
    PLoS One. 2019;14:e0210556.
    >> Share

  143. XIAO Y, Shen M, Ma S, Wen SW, et al
    The association between inter-twin birth weight discordance and hepatitis C: The United States 2011-2015 twin birth registration data.
    PLoS One. 2019;14:e0211683.
    >> Share

  144. SHILI-MASMOUDI S, Sogni P, de Ledinghen V, Esterle L, et al
    Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    PLoS One. 2019;14:e0211286.
    >> Share

  145. SHTEYER E, Shekhtman L, Zinger T, Harari S, et al
    Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.
    PLoS One. 2019;14:e0212252.
    >> Share

  146. SHENGE JA, Odaibo GN, Olaleye DO
    Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0210724.
    >> Share

  147. ARENDS RM, Nelwan EJ, Soediro R, van Crevel R, et al
    Associations between impulsivity, risk behavior and HIV, HBV, HCV and syphilis seroprevalence among female prisoners in Indonesia: A cross-sectional study.
    PLoS One. 2019;14:e0207970.
    >> Share

  148. YANG RF, Liu Y, Zhao CY, Ding YX, et al
    A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?
    PLoS One. 2019;14:e0211795.
    >> Share

  149. HANSEN JF, Christiansen KM, Staugaard B, Moessner BK, et al
    Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.
    PLoS One. 2019;14:e0212036.
    >> Share

  150. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    >> Share

  151. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0212033.
    >> Share

  152. VILLAR LM, Geloneze B, Vasques ACJ, Pires MLE, et al
    Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals.
    PLoS One. 2019;14:e0211193.
    >> Share

  153. GRANADOS-GARCIA V, Flores YN, Diaz-Trejo LI, Mendez-Sanchez L, et al
    Estimating the prevalence of hepatitis C among intravenous drug users in upper middle income countries: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0212558.
    >> Share

  154. GANOVA-RAEVA L, Dimitrova Z, Alexiev I, Punkova L, et al
    HCV transmission in high-risk communities in Bulgaria.
    PLoS One. 2019;14:e0212350.
    >> Share

  155. JONES EA, Linas BP, Truong V, Burgess JF, et al
    Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    PLoS One. 2019;14:e0213745.
    >> Share

  156. LE NGOC C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, et al
    Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam.
    PLoS One. 2019;14:e0212734.
    >> Share

  157. HUANG CH, Wu LS, Jeng WJ, Cheng YF, et al
    In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.
    PLoS One. 2019;14:e0212770.
    >> Share

  158. BUGGISCH P, Wursthorn K, Stoehr A, Atanasov PK, et al
    Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    PLoS One. 2019;14:e0214795.
    >> Share

  159. AHSAN A, Khan AZ, Javed H, Mirza S, et al
    Estimation of hepatitis C prevalence in the Punjab province of Pakistan: A retrospective study on general population.
    PLoS One. 2019;14:e0214435.
    >> Share

  160. LEE YC, Hu TH, Hung CH, Lu SN, et al
    The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2019;14:e0214323.
    >> Share

  161. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0215559.
    >> Share

  162. Retraction: Role of Hepatitis C Virus Induced Osteopontin in Epithelial to Mesenchymal Transition, Migration and Invasion of Hepatocytes.
    PLoS One. 2019;14:e0216026.
    >> Share

  163. Retraction: Activation of TGF-beta1 Promoter by Hepatitis C Virus-Induced AP-1 and Sp1: Role of TGF-beta1 in Hepatic Stellate Cell Activation and Invasion.
    PLoS One. 2019;14:e0216025.
    >> Share

  164. CHIKOVANI I, Ompad DC, Uchaneishvili M, Sulaberidze L, et al
    On the way to Hepatitis C elimination in the Republic of Georgia-Barriers and facilitators for people who inject drugs for engaging in the treatment program: A formative qualitative study.
    PLoS One. 2019;14:e0216123.
    >> Share

  165. COSTA VD, Brandao-Mello CE, Nunes EP, Dos Santos Silva PGC, et al
    Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    PLoS One. 2019;14:e0216327.
    >> Share

  166. COSSAIS S, Schwarzinger M, Pol S, Fontaine H, et al
    Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage.
    PLoS One. 2019;14:e0215596.
    >> Share

  167. CHEN M, Ma Y, Chen H, Dai J, et al
    Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China.
    PLoS One. 2019;14:e0217010.
    >> Share

  168. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    >> Share

  169. GEBOY AG, Nichols WL, Fernandez SJ, Desale S, et al
    Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.
    PLoS One. 2019;14:e0216459.
    >> Share

  170. CHAILLON A, Mehta SR, Hoenigl M, Solomon SS, et al
    Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    PLoS One. 2019;14:e0217964.
    >> Share

  171. GASTALDI G, Gomes D, Schneiter P, Montet X, et al
    Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients.
    PLoS One. 2019;14:e0217751.
    >> Share

  172. COFFIN PO, Santos GM, Behar E, Hern J, et al
    Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs.
    PLoS One. 2019;14:e0217471.
    >> Share

  173. RODRIGUEZ-OSORIO I, Mena A, Meijide H, Morano L, et al
    Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.
    PLoS One. 2019;14:e0217052.
    >> Share

  174. PAVICIC IVELJA M, Ivic I, Dolic K, Mestrovic A, et al
    Evaluation of cerebrovascular reactivity in chronic hepatitis C patients using transcranial color Doppler.
    PLoS One. 2019;14:e0218206.
    >> Share

  175. BAROCAS JA, So-Armah K, Cheng DM, Lioznov D, et al
    Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naive persons with alcohol use in Russia.
    PLoS One. 2019;14:e0218852.
    >> Share

  176. BREZZI M, Bertisch B, Roelens M, Moradpour D, et al
    Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    PLoS One. 2019;14:e0218706.
    >> Share

  177. CAMMAROTA S, Citarella A, Guida A, Conti V, et al
    The inpatient hospital burden of comorbidities in HCV-infected patients: A population-based study in two Italian regions with high HCV endemicity (The BaCH study).
    PLoS One. 2019;14:e0219396.
    >> Share

  178. KATO K, Shimada N, Atsukawa M, Abe H, et al
    Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
    PLoS One. 2019;14:e0219022.
    >> Share

  179. CALNER P, Sperring H, Ruiz-Mercado G, Miller NS, et al
    HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center.
    PLoS One. 2019;14:e0218388.
    >> Share

  180. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0219508.
    >> Share

  181. JULICHER P, Chulanov VP, Pimenov NN, Chirkova E, et al
    Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis.
    PLoS One. 2019;14:e0219687.
    >> Share

  182. WANG M, Wang Y, Liu Y, Wang H, et al
    SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradation.
    PLoS One. 2019;14:e0219989.
    >> Share

  183. SOHOLM J, Holm DK, Mossner B, Madsen LW, et al
    Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
    PLoS One. 2019;14:e0220297.
    >> Share

  184. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Correction: Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0221142.
    >> Share

  185. PUGA MAM, Bandeira LM, Pompilio MA, Rezende GR, et al
    Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required.
    PLoS One. 2019;14:e0221265.
    >> Share

  186. KWO PY, Puenpatom A, Zhang Z, Hui SL, et al
    Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    PLoS One. 2019;14:e0218759.
    >> Share

  187. PEREZ AB, Chueca N, Macias J, Pineda JA, et al
    Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PLoS One. 2019;14:e0221231.
    >> Share

  188. CHUGH Y, Dhiman RK, Premkumar M, Prinja S, et al
    Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    PLoS One. 2019;14:e0221769.
    >> Share

  189. UYEI J, Taddei TH, Kaplan DE, Chapko M, et al
    Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
    PLoS One. 2019;14:e0221614.
    >> Share

  190. CROWLEY D, Cullen W, Lambert JS, Van Hout MC, et al
    Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
    PLoS One. 2019;14:e0222186.
    >> Share

  191. REZAEI N, Asadi-Lari M, Sheidaei A, Khademi S, et al
    Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis.
    PLoS One. 2019;14:e0198449.
    >> Share

  192. HELLE F, Brochot E, Fournier C, Descamps V, et al
    Correction: Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus.
    PLoS One. 2019;14:e0223022.
    >> Share

  193. EREN C
    An analysis on HBsAg, Anti-HCV, Anti-HIV(1/2) and VDRL test results in blood donors according to gender, age range and years.
    PLoS One. 2019;14:e0219709.
    >> Share

  194. SENKERIKOVA R, Frankova S, Jirsa M, Kreidlova M, et al
    PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
    PLoS One. 2019;14:e0222609.
    >> Share

  195. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0223287.
    >> Share

  196. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    >> Share

  197. GARCIA A, Moore Boffi S, Gayet-Ageron A, Vernaz N, et al
    Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.
    PLoS One. 2019;14:e0223649.
    >> Share

  198. RAYAN DA'AS S, Azzeh M
    Subgenotyping and genetic variability of hepatitis C virus in Palestine.
    PLoS One. 2019;14:e0222799.
    >> Share

  199. KUO YH, Kee KM, Hsu NT, Wang JH, et al
    Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening.
    PLoS One. 2019;14:e0222196.
    >> Share

  200. BRENNER N, Mentzer AJ, Butt J, Braband KL, et al
    Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
    PLoS One. 2019;14:e0210407.
    >> Share

  201. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    >> Share

  202. MOHD SUAN MA, Said SM, Lim PY, Azman AZF, et al
    Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study.
    PLoS One. 2019;14:e0224459.
    >> Share

  203. BLACKARD JT, Kong L, Rouster SD, Karns R, et al
    CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PLoS One. 2019;14:e0224523.
    >> Share

  204. ZHENG Z, Lin J, Lu Z, Su J, et al
    Mortality risk in the population of HIV-positive individuals in Southern China: A cohort study.
    PLoS One. 2019;14:e0210856.
    >> Share

  205. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    >> Share

  206. ZUCKERMAN AD, Douglas A, Whelchel K, Choi L, et al
    Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
    PLoS One. 2019;14:e0225434.
    >> Share

  207. HAMADEH A, Feng Z, Krahn M, Wong WWL, et al
    A model-based framework for chronic hepatitis C prevalence estimation.
    PLoS One. 2019;14:e0225366.
    >> Share

  208. SHENGE JA, Odaibo GN, Olaleye DO
    Correction: Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0225679.
    >> Share

  209. MUCKE MM, Maasoumy B, Dietz J, Mucke VT, et al
    Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy.
    PLoS One. 2019;14:e0224751.
    >> Share

  210. Retraction: Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2019;14:e0225971.
    >> Share

  211. PAGE K, Evans JL, Hahn JA, Vickerman P, et al
    HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.
    PLoS One. 2019;14:e0226166.
    >> Share

  212. FILHO HRM, Bierrenbach ALS, Capuani MLD, Mendrone A Jr, et al
    Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.
    PLoS One. 2019;14:e0226566.
    >> Share

  213. SHIFERAW E, Tadilo W, Melkie I, Shiferaw M, et al
    Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: A four year retrospective study.
    PLoS One. 2019;14:e0214755.
    >> Share

  214. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    >> Share

  215. MORRIS MD, Andrew E, Tan JY, Maher L, et al
    Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships.
    PLoS One. 2019;14:e0217811.
    >> Share

  216. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    >> Share

  217. ROBERTS H, Boktor SW, Waller K, Daar ZS, et al
    Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015.
    PLoS One. 2019;14:e0217455.
    >> Share

  218. FREMPONG MT, Ntiamoah P, Annani-Akollor ME, Owiredu WKBA, et al
    Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana.
    PLoS One. 2019;14:e0219922.
    >> Share

  219. YEN YH, Chen CH, Hung CH, Wang JH, et al
    Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.
    PLoS One. 2019;14:e0222605.
    >> Share

  220. O'CONNOR SM, Mixson-Hayden T, Ganova-Raeva L, Djibo DA, et al
    Integrated HIV surveillance finds recent adult hepatitis B virus (HBV) transmission and intermediate HBV prevalence among military in uncharacterized Caribbean country.
    PLoS One. 2019;14:e0222835.
    >> Share

  221. KUNISHIMA H, Yoshida E, Caputo J, Mikamo H, et al
    Estimating the national cost burden of in-hospital needlestick injuries among healthcare workers in Japan.
    PLoS One. 2019;14:e0224142.
    >> Share

  222. GALLAY P, Ure D, Bobardt M, Chatterji U, et al
    The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
    PLoS One. 2019;14:e0217433.
    >> Share

  223. WOLDEGIORGIS AE, Erku W, Medhin G, Berhe N, et al
    Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia.
    PLoS One. 2019;14:e0226890.
    >> Share

    January 2018
  224. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2018;13:e0190803.
    >> Share

  225. CHARRE C, Cotte L, Kramer R, Miailhes P, et al
    Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men.
    PLoS One. 2018;13:e0190340.
    >> Share

  226. CHEN SH, Lai HC, Chiang IP, Su WP, et al
    Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0190455.
    >> Share

  227. BOLOTIN S, Feld JJ, Garber G, Wong WWL, et al
    Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.
    PLoS One. 2018;13:e0191184.
    >> Share

  228. CHENG CH, Lin CC, Chen HL, Lin IT, et al
    Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.
    PLoS One. 2018;13:e0191799.
    >> Share

  229. DEL CAMPO JA, Garcia-Valdecasas M, Gil-Gomez A, Rojas A, et al
    Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
    PLoS One. 2018;13:e0191805.
    >> Share

  230. NDJOYI-MBIGUINO A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, et al
    Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon.
    PLoS One. 2018;13:e0190529.
    >> Share

  231. SAFREED-HARMON K, Hetherington KL, Aleman S, Alho H, et al
    Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
    PLoS One. 2018;13:e0190146.
    >> Share

  232. ZAHR NM
    Peripheral TNFalpha elevations in abstinent alcoholics are associated with hepatitis C infection.
    PLoS One. 2018;13:e0191586.
    >> Share

  233. KELLY ML, Riordan SM, Bopage R, Lloyd AR, et al
    Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study.
    PLoS One. 2018;13:e0192763.
    >> Share

  234. ANADOL E, Lust K, Boesecke C, Schwarze-Zander C, et al
    Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.
    PLoS One. 2018;13:e0191118.
    >> Share

  235. RATTANAVIPAPONG W, Anothaisintawee T, Teerawattananon Y
    Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis.
    PLoS One. 2018;13:e0193112.
    >> Share

  236. TARAMASSO L, Di Biagio A, Bovis F, Nicolini LA, et al
    Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in HIV/HCV co-infected patients.
    PLoS One. 2018;13:e0192627.
    >> Share

  237. CHENG PN, Chiu YC, Chiu HC, Chien SC, et al
    The characteristics of residents with unawareness of hepatitis C virus infection in community.
    PLoS One. 2018;13:e0193251.
    >> Share

  238. MAPOURE NY, Budzi MN, Eloumou SAFB, Malongue A, et al
    Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study.
    PLoS One. 2018;13:e0192406.
    >> Share

  239. MAUNOURY F, Clement A, Nwankwo C, Levy-Bachelot L, et al
    Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PLoS One. 2018;13:e0194329.
    >> Share

  240. DI POTO C, He S, Varghese RS, Zhao Y, et al
    Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection.
    PLoS One. 2018;13:e0192748.
    >> Share

  241. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0194163.
    >> Share

  242. ZEKRI AN, El-Sisi ER, Youssef ASE, Kamel MM, et al
    MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.
    PLoS One. 2018;13:e0193709.
    >> Share

  243. CARABALLO CORTES K, Rosinska M, Janiak M, Stepien M, et al
    Next-generation sequencing analysis of a cluster of hepatitis C virus infections in a haematology and oncology center.
    PLoS One. 2018;13:e0194816.
    >> Share

  244. NEMOZ B, Roger L, Leroy V, Poveda JD, et al
    Evaluation of the cobas(R) GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.
    PLoS One. 2018;13:e0194396.
    >> Share

  245. LI CW, Yang CJ, Sun HY, Tsai MS, et al
    Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan.
    PLoS One. 2018;13:e0194149.
    >> Share

  246. DES JARLAIS DC, Cooper HLF, Arasteh K, Feelemyer J, et al
    Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    PLoS One. 2018;13:e0194799.
    >> Share

  247. TI L, Socias ME, Wood E, Milloy MJ, et al
    The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
    PLoS One. 2018;13:e0194162.
    >> Share

  248. YAMAZAKI T, Joshita S, Umemura T, Usami Y, et al
    Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.
    PLoS One. 2018;13:e0195632.
    >> Share

  249. GOLIZEH M, Melendez-Pena CE, Ward BJ, Saeed S, et al
    Proteomic fingerprinting in HIV/HCV co-infection reveals serum biomarkers for the diagnosis of fibrosis staging.
    PLoS One. 2018;13:e0195148.
    >> Share

  250. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    >> Share

  251. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    >> Share

  252. HAMADA K, Saitoh S, Nishino N, Fukushima D, et al
    Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response.
    PLoS One. 2018;13:e0195173.
    >> Share

  253. MASHIBA T, Joko K, Kurosaki M, Ochi H, et al
    Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    PLoS One. 2018;13:e0194704.
    >> Share

  254. FISHER KA, Cahill LM, Broyles S, Rorke M, et al
    Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.
    PLoS One. 2018;13:e0196157.
    >> Share

  255. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    PLoS One. 2018;13:e0196301.
    >> Share

  256. OKUBO H, Ando H, Sorin Y, Nakadera E, et al
    Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.
    PLoS One. 2018;13:e0196747.
    >> Share

  257. JIMENEZ-SOUSA MA, Gomez-Moreno AZ, Pineda-Tenor D, Medrano LM, et al
    The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design.
    PLoS One. 2018;13:e0197115.
    >> Share

  258. MAWATARI S, Oda K, Tabu K, Ijuin S, et al
    The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    PLoS One. 2018;13:e0198642.
    >> Share

  259. NAKANO T, Moriya K, Koike K, Horie T, et al
    Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells.
    PLoS One. 2018;13:e0198345.
    >> Share

  260. BLANCO RY, Loureiro CL, Villalba JA, Sulbaran YF, et al
    Decreasing prevalence of Hepatitis B and absence of Hepatitis C Virus infection in the Warao indigenous population of Venezuela.
    PLoS One. 2018;13:e0197662.
    >> Share

  261. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    >> Share

  262. ZUCKERMAN A, Douglas A, Nwosu S, Choi L, et al
    Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
    PLoS One. 2018;13:e0199174.
    >> Share

  263. HAINSWORTH SW, Dietze PM, Wilson DP, Sutton B, et al
    Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
    PLoS One. 2018;13:e0198336.
    >> Share

  264. YEN YH, Kuo FY, Kee KM, Chang KC, et al
    APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
    PLoS One. 2018;13:e0199760.
    >> Share

  265. YAYA I, Roux P, Marcellin F, Wittkop L, et al
    Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
    PLoS One. 2018;13:e0199874.
    >> Share

  266. SCHAEFER B, Viveiros A, Al-Zoairy R, Blach S, et al
    Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    PLoS One. 2018;13:e0200750.
    >> Share

  267. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0200866.
    >> Share

  268. MIOTTO N, Mendes LC, Zanaga LP, Lazarini MSK, et al
    All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response.
    PLoS One. 2018;13:e0199941.
    >> Share

  269. TIEU HV, Laeyendecker O, Nandi V, Rose R, et al
    Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City.
    PLoS One. 2018;13:e0200269.
    >> Share

  270. SOOD A, Suryaprasad A, Trickey A, Kanchi S, et al
    The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.
    PLoS One. 2018;13:e0200461.
    >> Share

  271. CUYPERS L, Perez AB, Chueca N, Aldamiz-Echevarria T, et al
    Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
    PLoS One. 2018;13:e0201268.
    >> Share

  272. MOTOYAMA H, Tamori A, Kubo S, Uchida-Kobayashi S, et al
    Correction: Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    PLoS One. 2018;13:e0201423.
    >> Share

  273. EVON DM, Stewart PW, Amador J, Serper M, et al
    A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    PLoS One. 2018;13:e0196908.
    >> Share

  274. NEESGAARD B, Ruhwald M, Krarup HB, Weis N, et al
    Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail.
    PLoS One. 2018;13:e0201629.
    >> Share

  275. DEMSISS W, Seid A, Fiseha T
    Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia.
    PLoS One. 2018;13:e0196539.
    >> Share

  276. PARK H, Jeong D, Nguyen P, Henry L, et al
    Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.
    PLoS One. 2018;13:e0196452.
    >> Share

  277. GOUNTAS I, Sypsa V, Blach S, Razavi H, et al
    HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    PLoS One. 2018;13:e0202109.
    >> Share

  278. HSIEH YC, Jeng WJ, Huang CH, Teng W, et al
    Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    PLoS One. 2018;13:e0202777.
    >> Share

  279. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Birth-cohort HCV screening target in Thailand to expand and optimize the national HCV screening for public health policy.
    PLoS One. 2018;13:e0202991.
    >> Share

  280. WHITMILL A, Kim S, Rojas V, Gulraiz F, et al
    Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection.
    PLoS One. 2018;13:e0202524.
    >> Share

  281. SILVA CMD, Peder LD, Guelere AM, Horvath JD, et al
    Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    PLoS One. 2018;13:e0203272.
    >> Share

  282. VALENCIA LA ROSA J, Ryan P, Alvaro-Meca A, Troya J, et al
    HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
    PLoS One. 2018;13:e0204795.
    >> Share

  283. UCHIDA Y, Naiki K, Kouyama JI, Sugawara K, et al
    Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    PLoS One. 2018;13:e0205600.
    >> Share

  284. JUANBELTZ R, Martinez-Baz I, San Miguel R, Goni-Esarte S, et al
    Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients.
    PLoS One. 2018;13:e0205277.
    >> Share

  285. SCHNELL G, Krishnan P, Tripathi R, Beyer J, et al
    Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    PLoS One. 2018;13:e0205186.
    >> Share

  286. FAHMY AM, Khabir M, Blanchet M, Labonte P, et al
    LC3B is not recruited along with the autophagy elongation complex (ATG5-12/16L1) at HCV replication site and is dispensable for viral replication.
    PLoS One. 2018;13:e0205189.
    >> Share

  287. MCCLURE MW, Berliba E, Tsertsvadze T, Streinu-Cercel A, et al
    Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
    PLoS One. 2018;13:e0204974.
    >> Share

  288. MARTINEZ-RODRIGUEZ ML, Uribe-Noguez LA, Arroyo-Anduiza CI, Mata-Marin JA, et al
    Prevalence and risk factors of Occult Hepatitis C infections in blood donors from Mexico City.
    PLoS One. 2018;13:e0205659.
    >> Share

  289. CHENG PN, Chiu HC, Chiu YC, Chen SC, et al
    Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community.
    PLoS One. 2018;13:e0206947.
    >> Share

  290. JANG TY, Yeh ML, Huang CI, Lin ZY, et al
    Association of hyperuricemia with disease severity in chronic hepatitis C patients.
    PLoS One. 2018;13:e0207043.
    >> Share

  291. KHAN B, Duncan I, Saad M, Schaefer D, et al
    Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.
    PLoS One. 2018;13:e0206356.
    >> Share

  292. BUTI M, Dominguez-Hernandez R, Casado MA, Sabater E, et al
    Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    PLoS One. 2018;13:e0208036.
    >> Share

  293. CHOWDHURY P, Sahuc ME, Rouille Y, Riviere C, et al
    Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
    PLoS One. 2018;13:e0198226.
    >> Share

  294. RAU M, Schmitt J, Berg T, Kremer AE, et al
    Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
    PLoS One. 2018;13:e0208225.
    >> Share

  295. ABADIE R, Goldenberg S, Welch-Lazoritz M, Fisher CB, et al
    Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research.
    PLoS One. 2018;13:e0208410.
    >> Share

  296. BOUACIDA L, Suin V, Hutse V, Boudewijns M, et al
    Distribution of HCV genotypes in Belgium from 2008 to 2015.
    PLoS One. 2018;13:e0207584.
    >> Share

  297. JUANBELTZ R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, et al
    Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.
    PLoS One. 2018;13:e0208554.
    >> Share

  298. MADDEN A, Hopwood M, Neale J, Treloar C, et al
    Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    PLoS One. 2018;13:e0207226.
    >> Share

  299. BADAWI A, Di Giuseppe G, Arora P
    Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).
    PLoS One. 2018;13:e0208839.
    >> Share

  300. GUALERZI A, Bellan M, Smirne C, Tran Minh M, et al
    Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.
    PLoS One. 2018;13:e0209216.
    >> Share

  301. GALLACH M, Vergara M, da Costa JP, Miquel M, et al
    Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2018;13:e0208112.
    >> Share

  302. BILLA O, Chalouni M, Salmon D, Poizot-Martin I, et al
    Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.
    PLoS One. 2018;13:e0208657.
    >> Share

  303. PAPIC N, Zidovec Lepej S, Gorenec L, Grgic I, et al
    The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C.
    PLoS One. 2018;13:e0209481.
    >> Share

  304. KAWAGISHI N, Suda G, Nakamura A, Kimura M, et al
    Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    PLoS One. 2018;13:e0209615.
    >> Share

  305. LIU CH, Liu CJ, Su TH, Yang HC, et al
    Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    PLoS One. 2018;13:e0209299.
    >> Share

  306. EVANS H, Balasegaram S, Douthwaite S, Hunter L, et al
    An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department.
    PLoS One. 2018;13:e0198520.
    >> Share

  307. MATSUMOTO K, Wu Y, Kitazawa T, Fujita S, et al
    Cost of illness of hepatocellular carcinoma in Japan: A time trend and future projections.
    PLoS One. 2018;13:e0199188.
    >> Share

  308. MULLHAUPT B, Bruggmann P, Bihl F, Blach S, et al
    Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    PLoS One. 2018;13:e0209374.
    >> Share

  309. XAYDALASOUK K, Strobel M, Buisson Y, Black AP, et al
    Seroprevalence and risk factors of hepatitis B and C virus infections in female workers of Lao garment factories.
    PLoS One. 2018;13:e0199919.
    >> Share

  310. CHEN YY, Fang WH, Wang CC, Kao TW, et al
    Increased body fat percentage in patients with hepatitis B and C virus infection.
    PLoS One. 2018;13:e0200164.
    >> Share

  311. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    >> Share

  312. ABEL S, Cuzin L, Da Cunha S, Bolivard JM, et al
    Reaching the WHO target of testing persons in jails in prisons will need diverse efforts and resources.
    PLoS One. 2018;13:e0202985.
    >> Share

  313. OWUSU M, Bonney JK, Annan AA, Mawuli G, et al
    Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana.
    PLoS One. 2018;13:e0203699.
    >> Share

  314. KENNEDY K, Graham SM, Arora N, Shuhart MC, et al
    Hepatocellular carcinoma among US and non-US-born patients with chronic hepatitis B: Risk factors and age at diagnosis.
    PLoS One. 2018;13:e0204031.
    >> Share

  315. TAKAHASHI A, Moriya K, Ohira H, Arinaga-Hino T, et al
    Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.
    PLoS One. 2018;13:e0204772.
    >> Share

  316. GREGORI J, Soria ME, Gallego I, Guerrero-Murillo M, et al
    Rare haplotype load as marker for lethal mutagenesis.
    PLoS One. 2018;13:e0204877.
    >> Share

  317. DAVIS SM, Davidov D, Kristjansson AL, Zullig K, et al
    Qualitative case study of needle exchange programs in the Central Appalachian region of the United States.
    PLoS One. 2018;13:e0205466.
    >> Share

  318. SUIJKERBUIJK AWM, van Hoek AJ, Koopsen J, de Man RA, et al
    Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    PLoS One. 2018;13:e0207037.
    >> Share

  319. BARANYI A, Meinitzer A, Rothenhausler HB, Amouzadeh-Ghadikolai O, et al
    Metabolomics approach in the investigation of depression biomarkers in pharmacologically induced immune-related depression.
    PLoS One. 2018;13:e0208238.
    >> Share

  320. WERNER RN, Gaskins M, Nast A, Dressler C, et al
    Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.
    PLoS One. 2018;13:e0208107.
    >> Share

    January 2017
  321. ASSELAH T, Moreno C, Sarrazin C, Gschwantler M, et al
    Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naive Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
    PLoS One. 2017;12:e0168713.
    >> Share

  322. ZHU Z, Tran H, Mathahs MM, Moninger TO, et al
    HCV Induces Telomerase Reverse Transcriptase, Increases Its Catalytic Activity, and Promotes Caspase Degradation in Infected Human Hepatocytes.
    PLoS One. 2017;12:e0166853.
    >> Share

  323. WANG SC, Lai KR, Li CY, Chiang CS, et al
    The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities.
    PLoS One. 2017;12:e0164281.
    >> Share

  324. STAHMEYER JT, Rossol S, Liersch S, Guerra I, et al
    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
    PLoS One. 2017;12:e0169401.
    >> Share

  325. PUGA MA, Bandeira LM, Pompilio MA, Croda J, et al
    Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil.
    PLoS One. 2017;12:e0169195.
    >> Share

  326. KIM DY, Han KH, Jun B, Kim TH, et al
    Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    PLoS One. 2017;12:e0167770.
    >> Share

  327. HU J, Gu X, Tao X, Qian Y, et al
    Prevalence and Trends of HIV, Syphilis, and HCV in Migrant and Resident Men Who Have Sex with Men in Shandong, China: Results from a Serial Cross-Sectional Study.
    PLoS One. 2017;12:e0170443.
    >> Share

  328. DEGRE D, Serste T, Lasser L, Delwaide J, et al
    Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PLoS One. 2017;12:e0170933.
    >> Share

  329. INOUE T, Hmwe SS, Shimada N, Kato K, et al
    Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    PLoS One. 2017;12:e0170667.
    >> Share

  330. ZHAI N, Li H, Song H, Yang Y, et al
    Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling.
    PLoS One. 2017;12:e0170516.
    >> Share

  331. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Correction: Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2017;12:e0170913.
    >> Share

  332. TSUTSUMI T, Okushin K, Enooku K, Fujinaga H, et al
    Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver.
    PLoS One. 2017;12:e0170461.
    >> Share

  333. NIEN HC, Hsu SJ, Su TH, Yang PJ, et al
    High Serum Lipopolysaccharide-Binding Protein Level in Chronic Hepatitis C Viral Infection Is Reduced by Anti-Viral Treatments.
    PLoS One. 2017;12:e0170028.
    >> Share

  334. ZHANG C, Hua R, Cui Y, Wang S, et al
    Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance.
    PLoS One. 2017;12:e0171217.
    >> Share

  335. WELSCH C, Efinger M, von Wagner M, Herrmann E, et al
    Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    PLoS One. 2017;12:e0171755.
    >> Share

  336. RUIZ-EXTREMERA A, Pavon-Castillero EJ, Florido M, Munoz de Rueda P, et al
    Influence of HLA class I, HLA class II and KIRs on vertical transmission and chronicity of hepatitis C virus in children.
    PLoS One. 2017;12:e0172527.
    >> Share

  337. MIYAKI E, Hiraga N, Imamura M, Uchida T, et al
    Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.
    PLoS One. 2017;12:e0172412.
    >> Share

  338. KONDILI LA, Gaeta GB, Ieluzzi D, Zignego AL, et al
    Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.
    PLoS One. 2017;12:e0172159.
    >> Share

  339. LIN SY, Lin CL, Ju SW, Wang IK, et al
    Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study.
    PLoS One. 2017;12:e0173125.
    >> Share

  340. RALLON N, Garcia M, Garcia-Samaniego J, Rodriguez N, et al
    HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells.
    PLoS One. 2017;12:e0173943.
    >> Share

  341. GUPTA N, Kabahizi J, Mukabatsinda C, Walker TD, et al
    "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
    PLoS One. 2017;12:e0174148.
    >> Share

  342. GUINOISEAU T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, et al
    Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification.
    PLoS One. 2017;12:e0174852.
    >> Share

  343. KACZMAREK DJ, Kokordelis P, Kramer B, Glassner A, et al
    Alterations of the NK cell pool in HIV/HCV co-infection.
    PLoS One. 2017;12:e0174465.
    >> Share

  344. CHEN H, Chen L
    Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
    PLoS One. 2017;12:e0175189.
    >> Share

  345. KOMOLMIT P, Charoensuk K, Thanapirom K, Suksawatamnuay S, et al
    Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: A randomised double-blinded, placebo-control trial.
    PLoS One. 2017;12:e0174608.
    >> Share

  346. FERNANDEZ-CABALLERO JA, Alvarez M, Chueca N, Perez AB, et al
    The cobas(R) HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice.
    PLoS One. 2017;12:e0175564.
    >> Share

  347. YANG CM, Yoon JC, Park JH, Lee JM, et al
    Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
    PLoS One. 2017;12:e0175793.
    >> Share

  348. CHLIBEK R, Smetana J, Sosovickova R, Gal P, et al
    Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.
    PLoS One. 2017;12:e0175525.
    >> Share

  349. LE GUILLOU-GUILLEMETTE H, Pivert A, Bouthry E, Henquell C, et al
    Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.
    PLoS One. 2017;12:e0174651.
    >> Share

  350. CAPILENO YA, Van den Bergh R, Donchunk D, Hinderaker SG, et al
    Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0175562.
    >> Share

  351. PENE V, Lemasson M, Harper F, Pierron G, et al
    Role of cleavage at the core-E1 junction of hepatitis C virus polyprotein in viral morphogenesis.
    PLoS One. 2017;12:e0175810.
    >> Share

  352. FRIAS M, Rivero-Juarez A, Tellez F, Perez-Perez M, et al
    Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy.
    PLoS One. 2017;12:e0177141.
    >> Share

  353. MOQUEET N, Kanagaratham C, Gill MJ, Hull M, et al
    A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection.
    PLoS One. 2017;12:e0176282.
    >> Share

  354. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    >> Share

  355. CHANG CC, Hsu HJ, Yen JH, Lo SY, et al
    A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.
    PLoS One. 2017;12:e0177383.
    >> Share

  356. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    >> Share

  357. D'ARMINIO MONFORTE A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, et al
    Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    PLoS One. 2017;12:e0177402.
    >> Share

  358. AGGARWAL R, Chen Q, Goel A, Seguy N, et al
    Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    PLoS One. 2017;12:e0176503.
    >> Share

  359. CENTO V, Nguyen THT, Di Carlo D, Biliotti E, et al
    Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PLoS One. 2017;12:e0177352.
    >> Share

  360. ECKHARDT B, Winkelstein ER, Shu MA, Carden MR, et al
    Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    PLoS One. 2017;12:e0177341.
    >> Share

  361. HUNDIE GB, Raj VS, GebreMichael D, Pas SD, et al
    Genetic diversity of hepatitis C virus in Ethiopia.
    PLoS One. 2017;12:e0179064.
    >> Share

  362. NAIK AS, Owsianka A, Palmer BA, O'Halloran CJ, et al
    Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.
    PLoS One. 2017;12:e0175349.
    >> Share

  363. EL HADAD S, Al-Hamdan H, Linjawi S
    Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia.
    PLoS One. 2017;12:e0178225.
    >> Share

  364. ALVARO-MECA A, Berenguer J, Diaz A, Micheloud D, et al
    Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.
    PLoS One. 2017;12:e0179493.
    >> Share

  365. CHU PS, Nakamoto N, Taniki N, Ojiro K, et al
    On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    PLoS One. 2017;12:e0179096.
    >> Share

  366. LEE JW, Kim W, Kwon EK, Kim Y, et al
    Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    PLoS One. 2017;12:e0179094.
    >> Share

  367. CAPILENO YA, Van den Bergh R, Donchuk D, Hinderaker SG, et al
    Correction: Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan.
    PLoS One. 2017;12:e0180286.
    >> Share

  368. MASCIA C, Vita S, Zuccala P, Marocco R, et al
    Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.
    PLoS One. 2017;12:e0179400.
    >> Share

  369. ELSHERIF O, Bannan C, Keating S, McKiernan S, et al
    Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.
    PLoS One. 2017;12:e0178398.
    >> Share

  370. LIN HC, Xirasagar S, Lee HC, Huang CC, et al
    Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.
    PLoS One. 2017;12:e0179312.
    >> Share

  371. ISHIZAKI A, Tran VT, Nguyen CH, Tanimoto T, et al
    Discrepancies in prevalence trends for HIV, hepatitis B virus, and hepatitis C virus in Haiphong, Vietnam from 2007 to 2012.
    PLoS One. 2017;12:e0179616.
    >> Share

  372. BELAUNZARAN-ZAMUDIO PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, et al
    Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
    PLoS One. 2017;12:e0179931.
    >> Share

  373. SHIU TY, Huang SM, Shih YL, Chu HC, et al
    Correction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2017;12:e0181299.
    >> Share

  374. SNOW KJ, Richards AH, Kinner SA
    Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study.
    PLoS One. 2017;12:e0180646.
    >> Share

  375. LEVENTER-ROBERTS M, Hammerman A, Brufman I, Hoshen M, et al
    Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
    PLoS One. 2017;12:e0176858.
    >> Share

  376. LOPEZ-RODRIGUEZ R, Hernandez-Bartolome A, Borque MJ, Rodriguez-Munoz Y, et al
    Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.
    PLoS One. 2017;12:e0180927.
    >> Share

  377. DALGARD O, Weiland O, Noraberg G, Karlsen L, et al
    Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PLoS One. 2017;12:e0179764.
    >> Share

  378. ANDRE-GARNIER E, Besse B, Rodallec A, Ribeyrol O, et al
    An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.
    PLoS One. 2017;12:e0179562.
    >> Share

  379. NEUKAM K, Martinez AP, Culasso ACA, Ridruejo E, et al
    NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.
    PLoS One. 2017;12:e0182193.
    >> Share

  380. RUSSELLI G, Pizzillo P, Iannolo G, Barbera F, et al
    HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation.
    PLoS One. 2017;12:e0181683.
    >> Share

  381. SABET S, George MA, El-Shorbagy HM, Bassiony H, et al
    Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene.
    PLoS One. 2017;12:e0181723.
    >> Share

  382. MERDAN M, Bekiryazici Z, Kesemen T, Khaniyev T, et al
    Deterministic stability and random behavior of a Hepatitis C model.
    PLoS One. 2017;12:e0181571.
    >> Share

  383. STELZL E, Haas B, Bauer B, Zhang S, et al
    First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing.
    PLoS One. 2017;12:e0181273.
    >> Share

  384. TAN WG, Zubkova I, Kachko A, Wells F, et al
    Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
    PLoS One. 2017;12:e0181578.
    >> Share

  385. HUGHES MG JR, Tucker WW, Reddy S, Brier ME, et al
    Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition.
    PLoS One. 2017;12:e0180719.
    >> Share

  386. SAGNELLI C, Uberti-Foppa C, Hasson H, Bellini G, et al
    Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    PLoS One. 2017;12:e0181890.
    >> Share

  387. NAGAOKI Y, Imamura M, Aikata H, Daijo K, et al
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    PLoS One. 2017;12:e0182710.
    >> Share

  388. HUANG CM, Chang KC, Hung CH, Chiu KW, et al
    Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
    PLoS One. 2017;12:e0182204.
    >> Share

  389. DE WEGGHELEIRE A, An S, De Baetselier I, Soeung P, et al
    A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening.
    PLoS One. 2017;12:e0183530.
    >> Share

  390. BUTT ZA, Shrestha N, Wong S, Kuo M, et al
    A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia.
    PLoS One. 2017;12:e0183609.
    >> Share

  391. COUTO I, Victoria M, Veloso VG, Rodrigues L, et al
    Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
    PLoS One. 2017;12:e0174453.
    >> Share

  392. CARRIERI MP, Marcellin F, Fressard L, Preau M, et al
    Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).
    PLoS One. 2017;12:e0171645.
    >> Share

  393. MANICKAM C, Wachtman L, Martinot AJ, Giavedoni LD, et al
    Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
    PLoS One. 2017;12:e0170240.
    >> Share

  394. SHIER MK, Iles JC, El-Wetidy MS, Ali HH, et al
    Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia.
    PLoS One. 2017;12:e0184163.
    >> Share

  395. HERMETET C, Dubois F, Gaudy-Graffin C, Bacq Y, et al
    Continuum of hepatitis C care in France: A 20-year cohort study.
    PLoS One. 2017;12:e0183232.
    >> Share

  396. KJAERGAARD M, Thiele M, Jansen C, Staehr Madsen B, et al
    High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal.
    PLoS One. 2017;12:e0173992.
    >> Share

  397. ZHENG Z, Sze CW, Keng CT, Al-Haddawi M, et al
    Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model.
    PLoS One. 2017;12:e0184127.
    >> Share

  398. GOMEZ-MORENO AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sanchez-Ruano JJ, et al
    Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study.
    PLoS One. 2017;12:e0184404.
    >> Share

  399. VUTIEN P, Jin M, Le MH, Nguyen P, et al
    Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.
    PLoS One. 2017;12:e0183851.
    >> Share

  400. CHI X, Zhao X, Wang W, Niu Y, et al
    Fusion expression of Occludin extracellular loops and an alpha-helical bundle: A new research model for tight junction.
    PLoS One. 2017;12:e0175516.
    >> Share

  401. CHEN HC, Chung CH, Wang CH, Lin JC, et al
    Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection.
    PLoS One. 2017;12:e0175266.
    >> Share

  402. KEATING SM, Dodge JL, Norris PJ, Heitman J, et al
    The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study.
    PLoS One. 2017;12:e0181004.
    >> Share

  403. NAKAMURA M, Kanda T, Jiang X, Haga Y, et al
    Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
    PLoS One. 2017;12:e0177302.
    >> Share

  404. TUDESQ JJ, Dunyach-Remy C, Combescure C, Doncesco R, et al
    Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients.
    PLoS One. 2017;12:e0183372.
    >> Share

  405. ROSINSKA M, Parda N, Kolakowska A, Godzik P, et al
    Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.
    PLoS One. 2017;12:e0185055.
    >> Share

  406. CHIU NC, Su CW, Liu CA, Huang YH, et al
    Interval to vascularization development in cirrhotic precursor nodules in patients with hepatitis B and C virus co-infections.
    PLoS One. 2017;12:e0178841.
    >> Share

  407. UITTE DE WILLIGE S, Keane FM, Bowen DG, Malfliet JJMC, et al
    Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.
    PLoS One. 2017;12:e0178987.
    >> Share

  408. NAGATY A, Abd El-Wahab EW
    Real-life results of sofosbuvir based therapy in chronic hepatitis C -naive and -experienced patients in Egypt.
    PLoS One. 2017;12:e0184654.
    >> Share

  409. KIM YA, Trinh S, Thura S, Kyi KP, et al
    Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.
    PLoS One. 2017;12:e0181603.
    >> Share

  410. BIADGO B, Shiferaw E, Woldu B, Alene KA, et al
    Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: A three year retrospective study.
    PLoS One. 2017;12:e0180416.
    >> Share

  411. PARASCHIV S, Banica L, Nicolae I, Niculescu I, et al
    Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users.
    PLoS One. 2017;12:e0185866.
    >> Share

  412. GOUVEIA LR, Santos JC, Silva RD, Batista AD, et al
    Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics.
    PLoS One. 2017;12:e0182196.
    >> Share

  413. UEMURA H, Tsukada K, Mizushima D, Aoki T, et al
    Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
    PLoS One. 2017;12:e0186255.
    >> Share

  414. BURCHILL MA, Roby JA, Crochet N, Wind-Rotolo M, et al
    Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    PLoS One. 2017;12:e0186213.
    >> Share

  415. RIOUALEN C, Da Costa Q, Chetrit B, Charafe-Jauffret E, et al
    HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings.
    PLoS One. 2017;12:e0185400.
    >> Share

  416. DUFFY D, Mottez E, Ainsworth S, Buivan TP, et al
    An in vitro diagnostic certified point of care single nucleotide test for IL28B polymorphisms.
    PLoS One. 2017;12:e0183084.
    >> Share

  417. CHEN YI MEI SLG, Thompson AJ, Christensen B, Cunningham G, et al
    Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    PLoS One. 2017;12:e0185609.
    >> Share

  418. DULTZ G, Graubard BI, Martin P, Welker MW, et al
    Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry.
    PLoS One. 2017;12:e0186898.
    >> Share

  419. HARFOUCHE M, Chemaitelly H, Kouyoumjian SP, Mahmud S, et al
    Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.
    PLoS One. 2017;12:e0187177.
    >> Share

  420. ROZERA G, Fabbri G, Lorenzini P, Mastrorosa I, et al
    Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    PLoS One. 2017;12:e0187095.
    >> Share

  421. MAROT A, Henrion J, Knebel JF, Moreno C, et al
    Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    PLoS One. 2017;12:e0186715.
    >> Share

  422. KONDILI LA, Gaeta GB, Brunetto MR, Di Leo A, et al
    Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
    PLoS One. 2017;12:e0185728.
    >> Share

  423. LOGGI E, Galli S, Vitale G, Di Donato R, et al
    Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
    PLoS One. 2017;12:e0187755.
    >> Share

  424. KONERMAN MA, Lu D, Zhang Y, Thomson M, et al
    Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.
    PLoS One. 2017;12:e0187344.
    >> Share

  425. SHIMIZU JF, Pereira CM, Bittar C, Batista MN, et al
    Multiple effects of toxins isolated from Crotalus durissus terrificus on the hepatitis C virus life cycle.
    PLoS One. 2017;12:e0187857.
    >> Share

  426. STROFFOLINI T, Sagnelli E, Andriulli A, Colloredo G, et al
    Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis.
    PLoS One. 2017;12:e0185710.
    >> Share

  427. GARRIGA C, Manzanares-Laya S, Garcia de Olalla P, Gorrindo P, et al
    Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns.
    PLoS One. 2017;12:e0187893.
    >> Share

  428. CARLUCCI JG, Farooq SA, Sizemore L, Rickles M, et al
    Low hepatitis C antibody screening rates among an insured population of Tennessean Baby Boomers.
    PLoS One. 2017;12:e0188624.
    >> Share

  429. BRAGA ACS, Carneiro BM, Batista MN, Akinaga MM, et al
    Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.
    PLoS One. 2017;12:e0188467.
    >> Share

  430. CANINI L, Imamura M, Kawakami Y, Uprichard SL, et al
    HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
    PLoS One. 2017;12:e0187409.
    >> Share

  431. COMSTOCK E, Kim CW, Murphy A, Emmanuel B, et al
    Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis.
    PLoS One. 2017;12:e0188314.
    >> Share

  432. LU G, Huang J, Yang Q, Xu H, et al
    Identification and genetic characterization of hepacivirus and pegivirus in commercial equine serum products in China.
    PLoS One. 2017;12:e0189208.
    >> Share

  433. SMITH JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, et al
    Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence.
    PLoS One. 2017;12:e0189255.
    >> Share

    January 2016
  434. POOVORAWAN K, Pan-Ngum W, White LJ, Soonthornworasiri N, et al
    Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
    PLoS One. 2016;11:e0163095.
    >> Share

  435. SAMIMI-RAD K, Rahimnia R, Sadeghi M, Malekpour SA, et al
    Epidemic History of Hepatitis C Virus among Patients with Inherited Bleeding Disorders in Iran.
    PLoS One. 2016;11:e0162492.
    >> Share

  436. WAN Z, Chen Q, Chen X, Duo L, et al
    HCV Diversity among Chinese and Burmese IDUs in Dehong, Yunnan, China.
    PLoS One. 2016;11:e0163062.
    >> Share

  437. JIMENEZ-SOUSA MA, Gutierrez-Rivas M, Alvaro-Meca A, Garcia-Alvarez M, et al
    NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain.
    PLoS One. 2016;11:e0163197.
    >> Share

  438. IDE T, Eguchi Y, Harada M, Ishii K, et al
    Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.
    PLoS One. 2016;11:e0163884.
    >> Share

  439. HASHIMOTO S, Yatsuhashi H, Abiru S, Yamasaki K, et al
    Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment.
    PLoS One. 2016;11:e0163644.
    >> Share

  440. NGUYEN LT, Gray E, O'Leary A, Carr M, et al
    The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors.
    PLoS One. 2016;11:e0163900.
    >> Share

  441. VAN SANTEN DK, de Vos AS, Matser A, Willemse SB, et al
    Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
    PLoS One. 2016;11:e0163488.
    >> Share

  442. MATSUNAMI K, Nishida N, Kaneko N, Ikeo K, et al
    Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C.
    PLoS One. 2016;11:e0164418.
    >> Share

  443. COLLI A, Fraquelli M, Prati D, Riva A, et al
    Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit.
    PLoS One. 2016;11:e0164452.
    >> Share

  444. GHORI NU, Shafique A, Hayat MQ, Anjum S, et al
    The Phylogeographic and Spatiotemporal Spread of HCV in Pakistani Population.
    PLoS One. 2016;11:e0164265.
    >> Share

  445. WHITE DA, Anderson ES, Pfeil SK, Deering LJ, et al
    Hepatitis C Virus Screening and Emergency Department Length of Stay.
    PLoS One. 2016;11:e0164831.
    >> Share

  446. DE AVILA AI, Gallego I, Soria ME, Gregori J, et al
    Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.
    PLoS One. 2016;11:e0164691.
    >> Share

  447. ALRIC L, Besson C, Lapidus N, Jeannel J, et al
    Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.
    PLoS One. 2016;11:e0162965.
    >> Share

  448. FLISIAK R, Shiffman M, Arenas J, Cheinquer H, et al
    A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    PLoS One. 2016;11:e0164563.
    >> Share

  449. DAVITKOV P, Chandar AK, Hirsch A, Compan A, et al
    Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.
    PLoS One. 2016;11:e0163945.
    >> Share

  450. CHOI YH, Jin N, Kelly F, Sakthivel SK, et al
    Elevation of Alanine Aminotransferase Activity Occurs after Activation of the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver During Acute HCV Infection.
    PLoS One. 2016;11:e0165533.
    >> Share

  451. SIRAVENHA LG, Siravenha LQ, Madeira LD, Oliveira-Filho AB, et al
    Detection of HCV Persistent Infections in the Dental Pulp: A Novel Approach for the Detection of Past and Ancient Infections.
    PLoS One. 2016;11:e0165272.
    >> Share

  452. ITAKURA J, Kurosaki M, Hasebe C, Osaki Y, et al
    Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
    PLoS One. 2016;11:e0165339.
    >> Share

  453. MERAT SJ, Molenkamp R, Wagner K, Koekkoek SM, et al
    Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.
    PLoS One. 2016;11:e0165047.
    >> Share

  454. ZHANG Y, Cao Y, Zhang R, Zhang X, et al
    Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
    PLoS One. 2016;11:e0165658.
    >> Share

  455. LOFTFIELD E, O'Brien TR, Pfeiffer RM, Howell CD, et al
    Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.
    PLoS One. 2016;11:e0166036.
    >> Share

  456. SU FH, Wu CS, Sung FC, Chang SN, et al
    Correction: Chronic Hepatitis C Virus Infection Is Associated with the Development of Rheumatoid Arthritis: A Nationwide Population-Based Study in Taiwan.
    PLoS One. 2016;11:e0166508.
    >> Share

  457. MIDGARD H, Bramness JG, Skurtveit S, Haukeland JW, et al
    Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
    PLoS One. 2016;11:e0166451.
    >> Share

  458. PALMER BA, Fanning LJ
    Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness.
    PLoS One. 2016;11:e0167089.
    >> Share

  459. LEE KY, Chen YH, Hsu SC, Yu MJ, et al
    Phosphorylation of Serine 235 of the Hepatitis C Virus Non-Structural Protein NS5A by Multiple Kinases.
    PLoS One. 2016;11:e0166763.
    >> Share

  460. AIKEN T, Garber A, Thomas D, Hamon N, et al
    Donor IFNL4 Genotype Is Associated with Early Post-Transplant Fibrosis in Recipients with Hepatitis C.
    PLoS One. 2016;11:e0166998.
    >> Share

  461. CHANG ML, Kuo CJ, Huang HC, Chu YY, et al
    Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
    PLoS One. 2016;11:e0166712.
    >> Share

  462. GAMBATO M, Caro-Perez N, Gonzalez P, Canete N, et al
    Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon.
    PLoS One. 2016;11:e0166631.
    >> Share

  463. HAMAD HA, Thurston J, Teague T, Ackad E, et al
    The NS4A Cofactor Dependent Enhancement of HCV NS3 Protease Activity Correlates with a 4D Geometrical Measure of the Catalytic Triad Region.
    PLoS One. 2016;11:e0168002.
    >> Share

  464. PUIGVEHI M, Hernandez J, Broquetas T, Coll S, et al
    Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF(R)) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years.
    PLoS One. 2016;11:e0164883.
    >> Share

  465. NUNEZ-TORRES R, Macias J, Mancebo M, Frias M, et al
    The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
    PLoS One. 2016;11:e0168265.
    >> Share

  466. SARRAZIN C, Manns M, Calleja JL, Garcia-Samaniego J, et al
    HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
    PLoS One. 2016;11:e0168544.
    >> Share

  467. EL-GHITANY EM, Farghaly AG, Farag S, Abd El-Wahab EW, et al
    Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population.
    PLoS One. 2016;11:e0168649.
    >> Share

  468. VILLANI R, Facciorusso A, Bellanti F, Tamborra R, et al
    DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.
    PLoS One. 2016;11:e0167934.
    >> Share

  469. YASUI Y, Abe T, Kurosaki M, Higuchi M, et al
    Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.
    PLoS One. 2016;11:e0154558.
    >> Share

  470. BOCHAROV G, Meyerhans A, Bessonov N, Trofimchuk S, et al
    Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.
    PLoS One. 2016;11:e0168576.
    >> Share

  471. DE MIGUEL-DIEZ J, Lopez-de-Andres A, Jimenez-Garcia R, Puente-Maestu L, et al
    Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997-2012).
    PLoS One. 2016;11:e0166421.
    >> Share

  472. NJOKU OS, Manak MM, O'Connell RJ, Shutt AL, et al
    An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria.
    PLoS One. 2016;11:e0166711.
    >> Share

  473. LIMA K, de Souza Leal E, Cavalcanti AM, Salustiano DM, et al
    Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil.
    PLoS One. 2016;11:e0155854.
    >> Share

  474. FARSHADPOUR F, Taherkhani R, Tajbakhsh S, Gholizadeh Tangestani M, et al
    Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study.
    PLoS One. 2016;11:e0157615.
    >> Share

  475. KIM YI, Kim HS, Park JW
    Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
    PLoS One. 2016;11:e0157299.
    >> Share

  476. YEH CC, Wang WC, Wu CS, Sung FC, et al
    Association of Sjogrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis.
    PLoS One. 2016;11:e0161958.
    >> Share

  477. REMIS RS, Liu J, Loutfy MR, Tharao W, et al
    Prevalence of Sexually Transmitted Viral and Bacterial Infections in HIV-Positive and HIV-Negative Men Who Have Sex with Men in Toronto.
    PLoS One. 2016;11:e0158090.
    >> Share

  478. PIEPENBRINK MS, Samuel M, Zheng B, Carter B, et al
    Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users.
    PLoS One. 2016;11:e0158641.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016